Lupus Nephritis - Pipeline Review, H1 2016

Published: Apr, 2016 | Pages: 135 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Lupus Nephritis - Pipeline Review, H1 2016

Summary

Global Markets Direct's, ‘Lupus Nephritis - Pipeline Review, H1 2016', provides an overview of the Lupus Nephritis pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Lupus Nephritis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lupus Nephritis and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Lupus Nephritis
- The report reviews pipeline therapeutics for Lupus Nephritis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Lupus Nephritis therapeutics and enlists all their major and minor projects
- The report assesses Lupus Nephritis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Lupus Nephritis

Reasons to Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Lupus Nephritis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Lupus Nephritis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Content
Table of Contents 2

List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Lupus Nephritis Overview 9
Therapeutics Development 10
Pipeline Products for Lupus Nephritis - Overview 10
Pipeline Products for Lupus Nephritis - Comparative Analysis 11
Lupus Nephritis - Therapeutics under Development by Companies 12
Lupus Nephritis - Therapeutics under Investigation by Universities/Institutes 13
Lupus Nephritis - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Lupus Nephritis - Products under Development by Companies 17
Lupus Nephritis - Products under Investigation by Universities/Institutes 18
Lupus Nephritis - Companies Involved in Therapeutics Development 19
AbbVie Inc. 19
Asahi Kasei Pharma Corp. 20
Astellas Pharma Inc. 21
Azano Pharmaceuticals Inc. 22
Boehringer Ingelheim GmbH 23
Bristol-Myers Squibb Company 24
Deltanoid Pharmaceuticals Inc. 25
F. Hoffmann-La Roche Ltd. 26
FibroStatin SL 27
GlaxoSmithKline Plc 28
HanAll Biopharma Co., Ltd. 29
Invion Limited 30
Kineta, Inc. 31
MedImmune, LLC 32
Omeros Corporation 33
Takeda Pharmaceutical Company Limited 34
Zyrnat Biotherapeutics SL 35
Lupus Nephritis - Therapeutics Assessment 36
Assessment by Monotherapy Products 36
Assessment by Target 37
Assessment by Mechanism of Action 39
Assessment by Route of Administration 41
Assessment by Molecule Type 43
Drug Profiles 45
abatacept - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
anifrolumab - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
belimumab - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
BI-655064 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
BMS-986147 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
dalazatide - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
DP-001 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Drug to Antagonize Bradykinin Receptor B1 for Lupus Nephritis - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
FSMAB-26 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
HL-161 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
INV-103 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
ixazomib citrate - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
mizoribine - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Monoclonal Antibody for Lupus Nephritis - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
obinutuzumab - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
OMS-721 - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
P-Dex - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
RO-5461111 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Stem Cell Therapy for Autoimmune Diseases - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
venetoclax - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
voclosporin - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
Y-175L - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
ZY-11 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
Lupus Nephritis - Recent Pipeline Updates 90
Lupus Nephritis - Dormant Projects 124
Lupus Nephritis - Discontinued Products 126
Lupus Nephritis - Product Development Milestones 127
Featured News & Press Releases 127
Mar 29, 2016: Aurinia Announces Result from Data and Safety Monitoring Board for Its Phase 2b Study in Lupus Nephritis - Study to Continue as Planned 127
Mar 02, 2016: Aurina Receives FDA Fast Track Designation for Voclosporin for the Treatment of Lupus Nephritis 127
Feb 08, 2016: Aurinia Announces Preliminary Topline Data From its Open Label Aurion Study in Lupus Nephritis 128
Feb 02, 2016: Deltanoid Pharmaceuticals Announces Appointment of Douglas Jermasek as Chief Executive Officer 128
Jan 19, 2016: Aurinia Announces Completion of Patient Enrollment in Its Phase 2B AURA-LV Study in Lupus Nephritis 129
Dec 03, 2015: Ocata's Hemangio-derived Mesenchymal Cells Preserve Kidney Function and Extend Lifespan in Preclinical Model of Lupus Nephritis 130
Nov 24, 2015: Aurinia Pharmaceuticals Announces Outcome from Data and Safety Monitoring Board for Its Phase 2b Study in Lupus Nephritis - Study to Continue as Planned 130
Nov 10, 2015: Kineta, Seattle Children's Research Institute Present New Data Demonstrating Positive, Predictive Responses to Dalazatide In Lupus 131
Aug 24, 2015: Ocata Therapeutics Receives SBIR Grant from NIH to Develop Proprietary Hemangio-derived Mesenchymal Cell Therapy for Lupus Nephritis 132
Jun 17, 2015: ACT Research Suggests Role for Dalazatide in Blocking T Cells from Patients with Lupus 132
Appendix 134
Methodology 134
Coverage 134
Secondary Research 134
Primary Research 134
Expert Panel Validation 134
Contact Us 134
Disclaimer 135

List of Tables

Number of Products under Development for Lupus Nephritis, H1 2016 10
Number of Products under Development for Lupus Nephritis - Comparative Analysis, H1 2016 11
Number of Products under Development by Companies, H1 2016 12
Number of Products under Investigation by Universities/Institutes, H1 2016 13
Comparative Analysis by Late Stage Development, H1 2016 14
Comparative Analysis by Clinical Stage Development, H1 2016 15
Comparative Analysis by Early Stage Development, H1 2016 16
Products under Development by Companies, H1 2016 17
Products under Investigation by Universities/Institutes, H1 2016 18
Lupus Nephritis - Pipeline by AbbVie Inc., H1 2016 19
Lupus Nephritis - Pipeline by Asahi Kasei Pharma Corp., H1 2016 20
Lupus Nephritis - Pipeline by Astellas Pharma Inc., H1 2016 21
Lupus Nephritis - Pipeline by Azano Pharmaceuticals Inc., H1 2016 22
Lupus Nephritis - Pipeline by Boehringer Ingelheim GmbH, H1 2016 23
Lupus Nephritis - Pipeline by Bristol-Myers Squibb Company, H1 2016 24
Lupus Nephritis - Pipeline by Deltanoid Pharmaceuticals Inc., H1 2016 25
Lupus Nephritis - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 26
Lupus Nephritis - Pipeline by FibroStatin SL, H1 2016 27
Lupus Nephritis - Pipeline by GlaxoSmithKline Plc, H1 2016 28
Lupus Nephritis - Pipeline by HanAll Biopharma Co., Ltd., H1 2016 29
Lupus Nephritis - Pipeline by Invion Limited, H1 2016 30
Lupus Nephritis - Pipeline by Kineta, Inc., H1 2016 31
Lupus Nephritis - Pipeline by MedImmune, LLC, H1 2016 32
Lupus Nephritis - Pipeline by Omeros Corporation, H1 2016 33
Lupus Nephritis - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 34
Lupus Nephritis - Pipeline by Zyrnat Biotherapeutics SL, H1 2016 35
Assessment by Monotherapy Products, H1 2016 36
Number of Products by Stage and Target, H1 2016 38
Number of Products by Stage and Mechanism of Action, H1 2016 40
Number of Products by Stage and Route of Administration, H1 2016 42
Number of Products by Stage and Molecule Type, H1 2016 44
Lupus Nephritis Therapeutics - Recent Pipeline Updates, H1 2016 90
Lupus Nephritis - Dormant Projects, H1 2016 124
Lupus Nephritis - Dormant Projects (Contd..1), H1 2016 125
Lupus Nephritis - Discontinued Products, H1 2016 126